JNJ Q2 preliminary: sales $25.53B (+6.3%), EPS $1.96 (+8.9%)

JOHNSON & JOHNSON

2023-Q2 EPS reported $1.93 revenue$50,276,000,000

Net earnings $5.14B vs $4.81B; diluted EPS $1.96 vs $1.80 YoY.
MedTech sales $7.79B (+12.9%) driven by Abiomed and Electrophysiology growth.
Pharmaceutical sales $13.73B (+3.1%); DARZALEX +22.4%, TREMFYA +18.3%, CARVYKTI $117M.
Consumer Health sales $4.01B (+5.4%); OTC +12.0%, Skin Health/Beauty +2.0%.
Preliminary results subject to adjustment; six-month net earnings fell 49.1% due to $7.2B other expense (Kenvue).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.